US+1 646-781-8004
Europe+44-203-868-8738
APAC+91-744-778-0008
sales@meticulousresearch.com
Home Report
Store
Vaccines Market
Vaccines Market by Indication (Pneumococcal, Influenza, Rotavirus, Hepatitis, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type (Inactivated, Live Attenuated, Subunit Vaccines), Valence (Multivalent, Monovalent) - Global Forecast to 2028
Report ID:MRHC - 104377 Pages: 229 Nov-2021 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Vaccines Market is valued at $187 billion in 2021, with COVID-19 vaccines contributing $137 billion. A vaccine provides controlled exposure to a pathogen. Governments across the globe have been heavily focusing on minimizing the global disease burden, specifically for vaccine-preventable diseases. Vaccination has also been considered the first line of defense to avoid an endemic and pandemic situation leading to healthcare emergencies.
The growth in this market is majorly driven by the high prevalence of diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, a strong pipeline for vaccines, and the emergence of the COVID-19 pandemic. In addition, increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market. However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.
COVID-19 Impact Assessment
The sudden outbreak of COVID-19 since November 2019 led to a rise in mortality rates globally. Overall, 31% of cases, 45% of hospitalizations, 53% of ICU admissions, and 80% of deaths associated with COVID-19 were among adults aged 65 years and over, with the highest percentage of severe outcomes among persons aged 85 years and over.
With the rise in overall confirmed cases, the global population eagerly awaited a vaccine capable of combating the virus. The rising demand for coronavirus vaccines is expected to fuel the growth of the vaccines market. Although vaccine development traditionally required years to complete the necessary testing, governments and medical regulators speeded up vaccine development due to the severity of the pandemic. As of 27th July 2021, approximately 108 COVID-19 vaccines were in the clinical development phase, and 184 vaccines were in the pre-clinical development stage, while 21 vaccines were already approved states WHO.
Several initiatives have been undertaken by organizations, governments, and vaccine manufacturers to progress vaccine development and its distribution. The World Health Organization collaborated with scientists, businesses, and global health organizations to speed up the pandemic response through the ACT Accelerator. In March 2020, Operation Warp Speed (OWS) was launched by the U.S. government. OWS was commissioned to produce and deliver 300 million doses of safe and effective COVID-19 vaccines by January 2021. The COVAX initiative was launched in April 2020, which is a part of the World Health Organization’s (WHO) Access to COVID19 Tools (ACT) Accelerator, which is being spearheaded by the Coalition for Epidemic Preparedness Innovations (CEPI); Gavi, the Vaccine Alliance; and the WHO. The goal was to work with vaccine manufacturers to offer low-cost COVID-19 vaccines to countries.
Thus, all the above collaborative efforts are expected to increase coronavirus vaccines' production in the upcoming years, thereby propelling the overall vaccines market growth.
Click here to: Get Free Sample Pages of this Report
Technological Advancements in Vaccine Administration
Vaccine technology has evolved significantly during the last decade, profoundly changing the future of vaccine development. The introduction of genetic engineering has fueled many advances in vaccine development programs, leading to new products. Various virus vaccines that use the attenuated form of the virus have been developed through these methods. Also, new technologies enable the faster detection of viruses and allow for concentration levels to be kept high enough to generate an immune response.
Recent vaccine technologies are largely driven by the need to accelerate response times against emerging threats and make vaccines available for quick deployment. The increasing need to develop vaccines against difficult targets and improve delivery systems for maximum potency is also at the focus of innovation in the vaccines industry. The development of synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are a few of the technological advancements in vaccine delivery.
Therefore, technological advancements are expected to drive the emergence of new and more effective vaccines for various new indications, fueling the growth of the vaccines market.
Long Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
Due to the complexity of production and associated procedures, vaccine development is considered a costly, complex, and time-consuming procedure, often lasting for about 10–15 years. During production, outcomes may vary significantly due to infinite combinations of biological materials, microorganisms, equipment used, environmental conditions, and the steps followed during culturing. Also, the reagents and the methods used to monitor culture characteristics increase the complexity of the process, lengthening manufacturing timelines.
Further, product approvals from regulatory authorities require additional time as the authorities analyze the quality and efficacy of the product and the process through which the product has been created. The vaccines enter clinical trials after the manufacturers present adequate pre-clinical data on the vaccines’ safety to validate the vaccines' activity in humans. Even after approval, vaccine batches are tested for safety and stability each year to ensure adherence to the regulatory guidelines. Moreover, the longer the timelines, the higher the cost of manufacturing, which limits the entry of new manufacturers, thereby hindering the market’s growth.
Key Findings in the Global Vaccines Market Study:
The influenza segment is estimated to register the fastest growth in the vaccines market.
Rising awareness regarding the importance of influenza vaccination, rise in the government efforts for vaccination against influenza, and increasing clinical trials support the demand for influenza vaccines globally.
The intramuscular route of vaccine administration to register the fastest growth in the vaccines market.
The ease of intramuscular administration and quick absorption of vaccines administered through the intramuscular route is propelling the segment. Further, the COVID-19 pandemic is contributing to the segment growth as many of the COVID-19 vaccines which are launched are being administered through this route.
Multivalent vaccines to dominate the global vaccines market.
The launch of new multivalent vaccines, increasing investments by key players in the R&D of multivalent vaccines, and the technological advancements in multivalent vaccine production are the major factors attributed to the large share of this segment in the vaccines market.
Asia-Pacific: Fastest-growing Regional Market
North America is estimated to command the largest share of the global vaccines market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific will be the fastest-growing regional market due to the increase in the emergence of infectious diseases, a large population of patients suffering from diseases, rising public awareness for vaccination, and governmental support towards immunization.
Key Players
The report includes a competitive landscape based on extensive assessment of the key strategic developments that market participants have adopted over the past four years. The key players profiled in the global vaccines market report are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).
Scope of the Report:
Vaccines Market, by Indication
- Pneumococcal Diseases
- Influenza
- Human Papilloma Virus (HPV)
- DTP
- Meningococcal Disease
- MMR
- Rotavirus
- Poliomyelitis (Polio)
- Hepatitis
- Other Indications
(Note: Other indications include varicella, herpes zoster vaccines, chlorella, severe acute respiratory syndrome, and rabies diseases)
Vaccines Market, by Route of Administration
- Intramuscular
- Subcutaneous
- Oral
- Other Routes of Administration
(Note: Other routes of administration include intradermal, transcutaneous, and nasal)
Vaccines Market, by Type
- Live Attenuated Vaccines
- Inactivated Vaccines
- Subunit and Conjugate vaccines
- Toxoid Vaccines
- Combination Vaccines
Vaccines Market, by Valence
- Monovalent
- Polyvalent (Multivalent)
COVID-19 Vaccines Market
- Prevalence
- COVID-19 Vaccines Market Size and Forecast
- Initiatives for Coronavirus Vaccine Development
- Authorized Vaccines & Phase 3 Vaccine Candidates
- COVID-19 Vaccine Pipeline Analysis
- Purchase Data for Covid-19 Vaccines
- Vaccination Coverage
Vaccines Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
The global vaccines market covers the market size & forecasts the vaccines used against infectious diseases like pneumococcal disease, influenza, DTP, HPV, meningococcal disease, polio, MMR, rotavirus, hepatitis, and other indications, which include varicella, herpes zoster, chlorella, COVID-19, and rabies. The vaccines market studied in this report involves the value analysis of various segments and sub-segments of vaccines at regional and country levels.
The global vaccines market is estimated to be $187 billion in 2021, with COVID-19 vaccines contributing to $137 billion.
Based on antigen type, the subunit and conjugate vaccines segment is estimated to account for the largest share of the global vaccines market due to long-term immunity and high safety and stability compared to other antigens.
In 2021, the pneumococcal diseases segment is estimated to account for the largest share of the global vaccines market due to the increasing prevalence of pneumococcal diseases like pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and initiatives by government organizations to control the outbreak of pneumococcal diseases.
The high prevalence of diseases, increasing government initiatives towards immunization, technological advancement in the vaccines industry, a strong pipeline for vaccines, and the emergence of the COVID-19 pandemic. Further, increasing epidemic potential, growing focus on therapeutic vaccines, and emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market.
The key players operating in the global vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.) among others.
The emerging economies like China and India based in Asia are projected to offer significant growth opportunities for the players in this market with the increase in the emergence of infectious diseases, a large population of patients suffering from diseases, rising public awareness for vaccination, and governmental support towards immunization.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1.Bottom-Up Approach
2.3.1.2.Top-Down Approach
2.3.1.3.Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Strong Product Pipeline for Vaccines
4.2.1.2. Increasing Government Focus on Immunization Programs
4.2.1.3. Technological Advancements in Vaccine Administration
4.2.2. Restraints
4.2.2.1. High Costs Involved in Vaccine Development
4.2.2.2. Long Timelines of Vaccine Manufacturing
4.2.3. Opportunities
4.2.3.1. Rising Prevalence of Diseases
4.2.3.2. Growing Focus on Therapeutic Vaccines
4.2.3.3. Growth Prospects in Emerging Markets
4.2.3.4. Increasing Use of Adjuvants in Vaccines
4.2.4. Challenges
4.2.4.1. Product Recalls
4.2.4.2. Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.1. Introduction
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papillomavirus (HPV)
6.5. Diphtheria, Tetanus, and Pertussis (DTP)
6.6. Meningococcal Disease
6.7. Measles, Mumps, and Rubella (MMR)
6.8. Rotavirus
6.9. Poliomyelitis (Polio)
6.10. Hepatitis
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other Routes of Administration
8. Global Vaccines Market, by Type
8.1. Introduction
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live-Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.1. Introduction
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global COVID-19 Vaccines Market
10.1. Introduction
10.2. Prevalence
10.3. COVID-19 Market Size & Forecast
10.4. Initiatives for Coronavirus Vaccine Development
10.5. Authorized Vaccines & Phase 3 Vaccine Candidates
10.6. COVID-19 Vaccine Pipeline Analysis
10.7. Purchase Data for COVID-19 Vaccines
10.8. Vaccination Coverage
11. Global Vaccines Market, by Geography
11.1. Introduction
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. U.K.
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe (RoE)
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Rest of Asia-Pacific (RoAPAC)
11.5. Latin America
11.6. Middle East & Africa (MEA)
12. Competitive Landscape
12.1. Introduction
12.2. Key Growth Strategies
12.3. Competitive Benchmarking
12.4. Market Share Analysis
13. Company Profiles
13.1. Sanofi
13.1.1. Business Overview
13.1.2. Financial Overview
13.1.3. Product Portfolio
13.1.4. Product Pipeline
13.1.5. Strategic Developments
13.2. Merck & Co., Inc.
13.2.1. Business Overview
13.2.2. Financial Overview
13.2.3. Product Portfolio
13.2.4. Product Pipeline
13.2.5. Strategic Developments
13.3. GlaxoSmithKline plc.
13.3.1. Business Overview
13.3.2. Financial Overview
13.3.3. Product Portfolio
13.3.4. Product Pipeline
13.3.5. Strategic Developments
13.4. Pfizer, Inc.
13.4.1. Business Overview
13.4.2. Financial Overview
13.4.3. Product Portfolio
13.4.4. Product Pipeline
13.4.5. Strategic Developments
13.5. Johnson & Johnson
13.5.1. Business Overview
13.5.2. Financial Overview
13.5.3. Product Portfolio
13.5.4. Product Pipeline
13.5.5. Strategic Developments
13.6. Daiichi Sankyo Co., Ltd.
13.6.1. Business Overview
13.6.2. Financial Overview
13.6.3. Product Portfolio
13.6.4. Product Pipeline
13.6.5. Strategic Developments
13.7. Takeda Pharmaceutical Company Limited
13.7.1. Business Overview
13.7.2. Financial Overview
13.7.3. Product Portfolio
13.7.4. Product Pipeline
13.7.5. Strategic Developments
13.8. CSL Limited
13.8.1. Business Overview
13.8.2. Financial Overview
13.8.3. Product Portfolio
13.8.4. Product Pipeline
13.8.5. Strategic Developments
13.9. Emergent BioSolutions Inc.
13.9.1. Business Overview
13.9.2. Financial Overview
13.9.3. Product Portfolio
13.9.4. Product Pipeline
13.9.5. Strategic Developments
13.10. AstraZeneca PLC
13.10.1. Business Overview
13.10.2. Financial Overview
13.10.3. Product Portfolio
13.10.4. Strategic Developments
14. Appendix
14.1. Questionnaire
14.2. Available Customization
List of Tables
Table 1 Global Vaccines Market Drivers: Impact Analysis (2021–2028)
Table 2 Global Vaccines Market Restraints: Impact Analysis (2021–2028)
Table 3 Key Government Regulatory Agencies
Table 4 List of Some of the Promising Vaccines in the Pipeline
Table 5 Average Selling Price (ASP) of Key Vaccines, by Region (USD/Unit)
Table 6 Global Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 7 Overview: Pneumococcal Disease
Table 8 Pneumococcal Diseases: Vaccines in the Pipeline
Table 9 Key Companies Offering Pneumococcal Vaccines
Table 10 Vaccines Market Size for Pneumococcal Disease, by Country/Region, 2019–2028 (USD Million)
Table 11 Overview: Influenza
Table 12 Influenza: Vaccines in the Pipeline
Table 13 Key Companies Offering Influenza Vaccines
Table 14 Vaccines Market Size for Influenza, by Country/Region, 2019–2028 (USD Million)
Table 15 Overview: HPV
Table 16 HPV Vaccine Prices (As of November 2020)
Table 17 Vaccines Market Size for Human Papillomavirus (HPV), by Country/Region,
2019–2028 (USD Million)
Table 18 Overview: Diphtheria, Tetanus, and Pertussis (DTP)
Table 19 Key Companies Offering DTP Vaccines
Table 20 Vaccines Market Size for Diphtheria, Tetanus, and Pertussis (DTP),
by Country/Region, 2019–2028 (USD Million)
Table 21 Overview: Meningococcal Disease
Table 22 Marketed Meningococcal Vaccine Combinations
Table 23 Key Companies Offering Meningococcal Vaccines
Table 24 Vaccines Market Size for Meningococcal Disease, by Country/Region, 2019–2028 (USD Million)
Table 25 Overview: Measles, Mumps, and Rubella
Table 26 Key Companies Offering MMR Vaccines
Table 27 Vaccines Market Size for Measles, Mumps, and Rubella (MMR), by Country/Region, 2019–2028 (USD Million)
Table 28 Overview: Rotavirus Disease
Table 29 Key Companies Offering Rotavirus Vaccines
Table 30 Vaccines Market Size for Rotavirus, by Country/Region, 2019–2028 (USD Million)
Table 31 Overview: Poliomyelitis (Polio)
Table 32 Polio Cases and Endemic Countries
Table 33 Key Companies Offering Polio Vaccines
Table 34 Vaccines Market Size for Polio, by Country/Region, 2019–2028 (USD Million)
Table 35 Overview: Hepatitis A
Table 36 Overview: Hepatitis B
Table 37 Key Companies Offering Hepatitis Vaccines
Table 38 Vaccines Market Size for Hepatitis, by Country/Region, 2019–2028 (USD Million)
Table 39 Vaccines Market Size for Other Indications, by Country/Region, 2019–2028
(USD Million)
Table 40 Global Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 41 Intramuscular Sites of Vaccine Administration, by Age Group
Table 42 Vaccines for Intramuscular Administration
Table 43 Key Companies Offering Intramuscular Vaccines
Table 44 Intramuscular Vaccines Market Size, by Country/Region, 2019–2028
(USD Million)
Table 45 Administration Sites for Subcutaneous Vaccines, by Age Group
Table 46 Vaccines for Subcutaneous Administration
Table 47 Key Companies Offering Subcutaneous Vaccines
Table 48 Subcutaneous Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 49 Key Companies Offering Oral Vaccines
Table 50 Oral Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 51 Vaccines Market Size for Other Routes of Administration, by Country/Region, 2019–2028 (USD Million)
Table 52 Types of Vaccines, by Antigen
Table 53 Global Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 54 Companies Offering Subunit and Conjugate Vaccines
Table 55 Subunit & Conjugate Vaccines Market Size, by Country/Region, 2019–2028
(USD Million)
Table 56 Approved Inactivated Coronavirus Vaccines (As of 23/07/2021)
Table 57 Inactivated Coronavirus Vaccines in Development (As of 23/07/2021)
Table 58 Companies Offering Inactivated Vaccines
Table 59 Inactivated Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 60 Live-Attenuated COVID-19 Candidate Vaccines
Table 61 Companies Offering Live-Attenuated Vaccines
Table 62 Live-Attenuated Vaccines Market Size, by Country/Region, 2019–2028
(USD Million)
Table 63 Toxoid Vaccines Used in the Vaccination Schedule
Table 64 Companies Offering Toxoid Vaccines
Table 65 Toxoid Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 66 Companies Offering Combination Vaccines
Table 67 Combination Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 68 Global Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 69 Multivalent Vaccines for Children (Available)
Table 70 Companies Offering Multivalent Vaccines
Table 71 Multivalent Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 72 Malaria, Ebola, Dengue, and Coronavirus Vaccines in the Pipeline
Table 73 Companies Offering Monovalent Vaccines
Table 74 Monovalent Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 75 Overview: Coronavirus Disease (COVID-19)
Table 76 Coronavirus Confirmed Cases (As of 29/07/2021)
Table 77 Vaccines Market Size for Coronavirus Disease, by Country/Region, 2020–2028
(USD Million)
Table 78 Authorized/Approved Coronavirus Vaccines
Table 79 Some of the Vaccine Candidates in Phase 3 Development
Table 80 Coronavirus Vaccine Confirmed and Projected Dose Purchases, by Country (As of December 2020)
Table 81 Global Vaccines Market Size (Excluding COVID-19), by Country/Region, 2019– 2028 (USD Million)
Table 82 North America: Vaccines Market Size, by Country, 2019–2028 (USD Million)
Table 83 North America: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 84 North America: Vaccines Market Size, by Route Of Administration, 2019–2028 (USD Million)
Table 85 North America: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 86 North America: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 87 Influenza Burden in the U.S., 2010–2020
Table 88 Some of the Coronavirus Vaccines in Development in the U.S. (As of 24/06/2021)
Table 89 U.S.: Macro Indicators
Table 90 U.S.: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 91 U.S.: Vaccines Market Size, by Route of Administration, 2019–2028 (USD Million)
Table 92 U.S.: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 93 U.S.: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 94 Canada: Macro Indicators
Table 95 Canada: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 96 Canada: Vaccines Market Size, by Route Of Administration, 2019–2028 (USD Million)
Table 97 Canada: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 98 Canada: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 99 Europe: Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 100 Europe: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 101 Europe: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 102 Europe: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 103 Europe: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 104 Germany: Macro Indicators
Table 105 Germany: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 106 Germany: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 107 Germany: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 108 Germany: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 109 U.K.: Macro Indicators
Table 110 U.K.: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 111 U.K.: Vaccines Market Size, by Route of Administration, 2019–2028 (USD Million)
Table 112 U.K.: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 113 U.K.: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 114 France: Macro Indicators
Table 115 France: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 116 France: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 117 France: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 118 France: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 119 Italy: Macro Indicators
Table 120 Italy: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 121 Italy: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 122 Italy: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 123 Italy: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 124 Spain: Macro Indicators
Table 125 Spain: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 126 Spain: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 127 Spain: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 128 Spain: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 129 RoE: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 130 RoE: Vaccines Market Size, by Route of Administration, 2019–2028 (USD Million)
Table 131 RoE: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 132 RoE: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 133 Asia-Pacific: Vaccines Market Size, by Country/Region, 2019–2028 (USD Million)
Table 134 Asia-Pacific: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 135 Asia-Pacific: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 136 Asia-Pacific: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 137 Asia-Pacific: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 138 Japan: Macro Indicators
Table 139 Japan: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 140 Japan: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 141 Japan: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 142 Japan: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 143 Coronavirus Vaccines Approved/In Development in China (As of 03/01/2021)
Table 144 China: Macro Indicators
Table 145 China: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 146 China: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 147 China: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 148 China: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 149 Vaccine Prices in India
Table 150 India: Macro Indicators
Table 151 India: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 152 India: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 153 India: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 154 India: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 155 RoAPAC: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 156 RoAPAC: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 157 RoAPAC: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 158 RoAPAC: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 159 Latin America: Vaccines Market Size, by Indication, 2019–2028 (USD Million)
Table 160 Latin America: Vaccines Market Size, by Route of Administration, 2019–2028
(USD Million)
Table 161 Latin America: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 162 Latin America: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 163 Middle East & Africa: Vaccines Market Size, by Indication, 2019–2028
(USD Million)
Table 164 Middle East & Africa: Vaccines Market Size, by Route of Administration,
2019–2028 (USD Million)
Table 165 Middle East & Africa: Vaccines Market Size, by Type, 2019–2028 (USD Million)
Table 166 Middle East & Africa: Vaccines Market Size, by Valence, 2019–2028 (USD Million)
Table 167 Number of Developments by Major Players, 2018–2021
Table 168 Vaccines Market: Competitive Benchmarking, by Product
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global Vaccines Market Size, by Indication, 2021–2028 (USD Million)
Figure 8 COVID-19 Vaccines Market 2021 Vs 2028 (USD Million)
Figure 9 Global Vaccines Market Size, by Route of Administration, 2021–2028
(USD Million)
Figure 10 Global Vaccines Market Size, by Type, 2021–2028 (USD Million)
Figure 11 Global Vaccines Market Size, by Valence, 2021–2028 (USD Million)
Figure 12 Vaccines Market Overview, by Region
Figure 13 Number of Health Products in the Pipeline: July 2021
Figure 14 Vaccine Projects in the Pipeline: 2020
Figure 15 Therapeutic Vaccines Being Developed for Cancer: 2011 and 2018
Figure 16 New Cancer Cases in Asia, Latin America, and the Caribbean: 2020–2040
Figure 17 Global Vaccines Market Size, by Indication, 2021–2028 (USD Million)
Figure 18 Influenza Vaccines Distribution: 2016–2021
Figure 19 Forecasted Global Demand for DTwP Vaccines: 2018–2032
Figure 20 MMR Vaccines Supply: 2016–2019
Figure 21 Global Vaccination Coverage Against Rotavirus: 2010–2020
Figure 22 U.S. Funding for Polio: 2015–2020
Figure 23 Routes of Vaccine Administration
Figure 24 Global Vaccines Market Size, by Route of Administration, 2021–2028
(USD Million)
Figure 25 Global Vaccines Market Size, by Type, 2021–2028 (USD Million)
Figure 26 Global Vaccines Market Size, by Valence, 2021–2028 (USD Million)
Figure 27 Coronavirus Vaccines in Development, by Phase
Figure 28 COVID-19 Vaccination Among Populations (As of 29/07/2021)
Figure 29 Global Vaccines Market Size, by Region, 2021–2028 (USD Million)
Figure 30 Geographic Snapshot: Vaccines Market, North America (Excluding COVID-19)
Figure 31 U.S. Funding for Global Polio: 2013–2020
Figure 32 Geographic Snapshot: Vaccines Market, Europe (Excluding COVID-19)
Figure 33 Increase in Immunization After Mandatory Vaccination
Figure 34 Increase in the Number of Registered Influenza Cases (2015–2019)
Figure 35 Spain: Increase in the Number of Biotechnology Companies (2010–2018)
Figure 36 Geographic Snapshot: Vaccines Market, Asia-Pacific (Excluding COVID-19)
Figure 37 India: Increase in Health Expenditure (2010–2020)
Figure 38 Cancer Incidence in the Middle East & Africa: 2020 and 2030
Figure 39 Key Growth Strategies Adopted by Leading Players, 2018–2021
Figure 40 Vaccines Market: Competitive Benchmarking, by Geography
Figure 41 Global Vaccines Market (Including COVID-19) Share, by Key Player, 2020 (%)
Figure 42 Sanofi: Financial Overview (2020)
Figure 43 Merck & Co., Inc.: Financial Overview (2020)
Figure 44 GlaxoSmithKline plc (GSK): Financial Overview (2020)
Figure 45 Pfizer, Inc.: Financial Overview (2020)
Figure 46 Johnson & Johnson (J&J): Financial Overview (2020)
Figure 47 Daichi Sankyo Co., Ltd.: Financial Overview (2020)
Figure 48 Takeda Pharmaceutical: Financial Overview (2020)
Figure 49 CSL Limited: Financial Overview (2020)
Figure 50 Emergent BioSolutions Inc.: Financial Overview (2020)
Figure 51 AstraZeneca PLC: Financial Overview (2020)
Related Reports
Real World Evidence Solutions Market - Global Opportunity Analysis and Industry Forecast (2021-2028)
Published Date: Jul-2022
RWE Oncology Market - Global Opportunity Analysis And Industry Forecasts (2022-2029)
Published Date: Jul-2022
Medical Aesthetics Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Jun-2022
Plasma Fractionation Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: May-2022
